Demand for estrogen patches surged 26% after the FDA removed a black box warning on hormone therapy in 2025 ...

More women are seeking treatment for menopause and perimenopause, driving a shortage of estrogen patches, one of the most ...

The estrogen patch shortage is real, but it's not the whole story. Here's what changed, why demand surged and what women can ...

For women in perimenopause and menopause, hormone therapy can be the difference between waking up every night at 3 a.m., ...

For men with locally advanced prostate cancer, transdermal estradiol (tE2) patches are noninferior to luteinizing hormone-releasing hormone (LHRH) agonists as ...

A flawed 2002 study shaped menopause care for two decades. Here’s what the science actually shows about estrogen patches and ...

After years of being a controversial way of treating symptoms of menopause, hormone therapy is making a comeback. That’s due to a wide range of factors, including a large body of data that shows how ...

With rising demand for hormone therapy for menopause, some women are scrambling to fill prescriptions by switching brands or dosages. Emily Padgett said she's on her third brand. - Emily Padgett Emily ...

Estrogen patches are hard to find right now. Here's what's behind the shortage and what your options are if your pharmacy is ...

The proportion of patients achieving a prostate-specific antigen nadir less than or equal to 0.2 ng/ml was exactly the same for patients treated with transdermal estradiol patches and those treated ...

Based on phase 3 trial findings, investigators conclude that transdermal estradiol should be a standard of care ADT option for patients with nonmetastatic prostate cancer. Transdermal estradiol (tE2) ...

A recent study published in The New England Journal of Medicine found that transdermal estradiol (tE2) therapy was ...